TARGET AUDIENCE
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal (GI) cancers.

OVERVIEW OF ACTIVITY
Given the prevalent nature of the disease, extensive resources are allocated to colorectal cancer research and education. Interestingly, however, although individually less frequently encountered, the collection of other noncolorectal GI cancers accounts for more per annum cancer-related deaths than those attributed to tumors of the colon and rectum combined. Among this collection of distinct tumor types, a few areas in particular — namely gastric, pancreatic and hepatocellular cancer — have witnessed several recent advances that have altered or have the potential to drastically alter current treatment considerations and approaches.

These video proceedings from a CME symposium held during the 2018 ASCO Annual Meeting feature discussions with leading researchers with an expertise in GI cancers regarding actual cases from their practices and the published data that drive clinical decision-making for patients in those and diverse other situations. By providing information on the latest research developments and their potential application to routine practice, this activity is designed to assist medical oncologists, hematology-oncology fellows and other healthcare providers with the formulation of up-to-date clinical management strategies.

LEARNING OBJECTIVES

• Review recent data on therapeutic advances and changing practice standards in colorectal and noncolorectal GI cancers, and integrate this information, as appropriate, into current clinical care.
• Develop a long-term care plan for individuals diagnosed with metastatic colorectal cancer, considering biomarker profile, tumor location, prior systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
• Use HER2 status, PD-L1 combined positive score, clinical factors and patient preferences to optimize the selection and sequence of systemic therapy for locally advanced or metastatic gastric/gastroesophageal cancer.
• Consider age, PS and other clinical and logistical factors in the selection of systemic therapy for patients with localized, locally advanced or metastatic pancreatic adenocarcinoma.
• Communicate the benefits and risks of available and emerging systemic interventions to patients with locally advanced or metastatic hepatocellular carcinoma.
• Appraise the rationale for and clinical data with commercially available and developmental immune checkpoint inhibitors in the treatment of GI cancers.
• Recall the design of ongoing clinical trials evaluating novel investigational agents in GI cancers, and counsel appropriately selected patients about availability and participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Charles S Fuchs, MD
Director, Yale Cancer Center
Physician-in-Chief, Smilow Cancer Hospital
New Haven, Connecticut

Board Member: CytomX Therapeutics; Consulting Agreements: Agios Pharmaceuticals Inc, Bain Capital, Bayer HealthCare Pharmaceuticals, Entrinsic Health Solutions LLC, Five Prime Therapeutics Inc, Genentech, KEW Group LLC, Lilly, Merck, Merrimack Pharmaceuticals Inc, Sanofi Genzyme, Taiho Oncology Inc, Unum.

Axel Grothey, MD
Professor of Oncology
West Cancer Center
University of Tennessee
Memphis, Tennessee

Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Genentech, Roche Laboratories Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Eisai Inc, Genentech.

Yelena Y Janjigian, MD
Assistant Attending Physician
Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Advisory Committee: Astellas Pharma Global Development Inc, Bristol-Myers Squibb Company, Lilly, Merck, Pfizer Inc; Consulting Agreements: Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Lilly.

Robin K Kelley, MD

Associate Professor of Clinical Medicine
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Advisory Committee: Genentech, TARGET PharmaSolutions Inc; Contracted Research: Agios Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Lilly, Merck, Novartis, Taiho Oncology Inc.

Andrew Ko, MD
Professor
Department of Medicine (Hematology/Oncology)
University of California, San Francisco
Helen Diller Family Comprehensive Cancer Center
San Francisco, California

Advisory Committee: ARMO BioSciences, Celgene Corporation, Rafael Pharmaceuticals Inc; Consulting Agreement: Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbGenomics Holding Ltd, Apexigen, Bristol-Myers Squibb Company, Celgene Corporation, Genentech, Halozyme Inc, Merck, Merrimack Pharmaceuticals Inc.

Scott Kopetz, MD, PhD
Associate Professor, Department of Gastrointestinal Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Genentech.

Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan

Advisory Committee: AbbVie Inc, Celgene Corporation, Halozyme Inc, Ipsen Biopharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Merck; Consulting Agreement: Lilly; Contracted Research: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Halozyme Inc, Lilly, Merck, Novartis; Speakers Bureau: Celgene Corporation, Ipsen Biopharmaceuticals Inc, Merck.

Andrew X Zhu, MD, PhD
Director, Liver Cancer Research
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, Lilly, Merck, Novartis, Sanofi Genzyme; Contracted Research: Bayer HealthCare Pharmaceuticals, Lilly, Merck, Novartis.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Bayer HealthCare Pharmaceuticals, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Gilead Sciences Inc, Ipsen Biopharmaceuticals Inc, Lilly and Taiho Oncology Inc.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: August 2018
Expiration date: August 2019